Breaking the mold: Overcoming resistance to immune checkpoint inhibitors

被引：3
|
作者：
Zhao, Menglu [1 ]
Yan, Chun-Yan [1 ]
Wei, Ya-Nan [1 ]
Zhao, Xi-He [1 ]
机构：
[1] China Med Univ, Shengjing Hosp, Dept Clin Oncol, Shenyang 110022, Peoples R China
来源：
ANTIVIRAL RESEARCH | 2023年 / 219卷
基金：
中国国家自然科学基金;
关键词：
PD-L1; Drug resistance; Bispecific antibody; Antibody drug conjugate (ADC); TUMOR MUTATIONAL BURDEN; T-CELLS; ANTITUMOR IMMUNITY; CANCER; IMMUNOTHERAPY; BLOCKADE; EFFICACY; RECEPTOR; PD-L1; EXPRESSION;
D O I：
10.1016/j.antiviral.2023.105720
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Immune checkpoint blockade-based therapies are effective against a sorts of cancers. However, drug resistance is a problem that cannot be ignored. This review intends to elucidate the mechanisms underlying drug tolerance induced by PD-1/PD-L1 inhibitors, as well as to outline proposed mechanism-based combination therapies and small molecule drugs that target intrinsic immunity and immune checkpoints. According to the differences of patients and types of cancer, the optimization of individualized combination therapy will help to enhance PD-1/ PD-L1-mediated immunoregulation, reduce chemotherapy resistance, and provide new ideas for chemotherapyresistant cancer.
引用
收藏
页数：11
相关论文
共 50 条
  • [21] Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
    Ouyang, Peng
    Wang, Lijuan
    Wu, Jianlong
    Tian, Yao
    Chen, Caiyun
    Li, Dengsheng
    Yao, Zengxi
    Chen, Ruichang
    Xiang, Guoan
    Gong, Jin
    Bao, Zhen
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
    Huang, Qian
    Lei, Yanna
    Li, Xiaoying
    Guo, Fukun
    Liu, Ming
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [23] Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
    Weber, Matthias M.
    Fottner, Christian
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (05) : 306 - 312
  • [24] Immune checkpoint inhibitors: a new era for esophageal cancer
    Zou, Li-Qing
    Yang, Xi
    Li, Yi-Da
    Zhu, Zheng-Fei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 731 - 738
  • [25] Determinants of Resistance to Checkpoint Inhibitors
    Tran, Linda
    Theodorescu, Dan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (05)
  • [26] Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview
    Kejamurthy, Priyatharcini
    Devi, K. T. Ramya
    MEDICAL ONCOLOGY, 2023, 41 (01)
  • [27] Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Vargas, Thaiz Rivera
    Apetoh, Lionel
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [28] Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?
    Lao, Yefang
    Shen, Daoming
    Zhang, Weili
    He, Rui
    Jiang, Min
    CANCERS, 2022, 14 (15)
  • [29] Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response
    Coschi, Courtney H.
    Juergens, Rosalyn A.
    CURRENT ONCOLOGY, 2024, 31 (01) : 1 - 23
  • [30] Resistance mechanisms to checkpoint inhibitors
    Weiss, Sarah A.
    Sznol, Mario
    CURRENT OPINION IN IMMUNOLOGY, 2021, 69 : 47 - 55
12345